Skip to main content
Yingji Chen on Muck Rack

Yingji Chen

As seen in: Nature, Wiley Online Library, PLOS ONE, BioRxiv, eLife
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingji

Contact Yingji, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

DPP9 inhibition boosts antitumor immunity by disrupting BRISC-mediated PD-L1 expression in clear cell renal cell carcinoma

|
By Wei Zhang, YUE WANG, Tao Feng, Tingting Cai, Wenfeng Wang, Shuxuan Zhu, Yingji Chen, Hailiang Zhang, Dingwei Ye, Chenji Wang, Kun Chang
| Nature Verified
Abstract Programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1) are key mediators of immune checkpoint blockade therapy in clear cell renal cell carcinoma (RCC). However, immune evasion and primary resistance often limit their efficacy, highlighting the need for improved strategies. Here, we identified dipeptidyl peptidase 9 (DPP9) as a critical regulator of PD-L1 expression in ccRCC.
Open in Who Shared View Duplicates (2) Issue with article?

Targeting the WSB2-NOXA axis in cancer cells for enhanced sensitivity to BCL-2 family protein inhibitors

|
By Dongyue Jiao, Kun Chang, Jiamin Jin, Yingji Chen
| eLife
eLife Assessment This study reports a fundamental observation concerning cell death regulation by the anti-apoptotic BCL2 family NOXA. The authors convincingly demonstrate that NOXA is destabilized through the interaction with WSB2, a substrate receptor in CRL5 ubiquitin ligase complex, sensitizing the cells to treatments. These are key findings for cell biologists and cancer researchers as they identified a new target impacting drug responsiveness in cancer therapies.
Open in Who Shared Issue with article?

Targeting the WSB2-NOXA Axis in Cancer Cells for Enhanced Sensitivity to BCL-2 Family Protein Inhibitors

|
By Dongyue Jiao, Kun Chang, Yingji Chen, Jiamin Jin
| BioRxiv
Abstract Anti-apoptotic BCL-2 family proteins are frequently overexpressed in various cancers, playing a pivotal role in cancer initiation and progression, as well as intrinsic or acquired resistance to therapy. Although inhibitors targeting BCL-2, such as Venetoclax, have shown efficacy in hematological malignancies, their therapeutic potential in solid tumors remains limited. Identifying novel molecular targets to overcome resistance to these inhibitors is of significant clinical importance.
Open in Who Shared Issue with article?
See all 10 articles